Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "SLC23A3-NHEJ1 readthrough" (ENSG00000280537) refers to a predicted fusion transcript generated by transcriptional readthrough between the SLC23A3 and NHEJ1 genes. While both parent genes encode proteins with distinct cellular functions—SLC23A3 encodes a transmembrane transporter for hypoxanthine, and NHEJ1 encodes a DNA repair factor—there is no evidence that the readthrough transcript encodes a functional protein or that it has specific biological, disease, or pharmacological relevance. This entity is likely the result of annotation or prediction pipelines identifying rare transcriptional or splicing events, rather than a validated molecular target. No direct aliases, classifications, functions, associated diseases, drugs, biomarkers, or safety concerns exist for this readthrough product; any relevant information applies only to the separate parental genes[2][5][4].
None known.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 23 member 3–Non-homologous end joining factor 1 readthrough (SLC23A3-NHEJ1 readthrough).